NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) today announced that its Enzo Clinical Labs subsidiary and Massachusetts-based Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea’s non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer.
Help employers find you! Check out all the jobs and post your resume.
